.jpg)
.png)
Image:
Body:
From TheHeart.org: Amsterdam, the Netherlands - An analysis of four phase-2 studies testing the effectiveness of AMG145 (Amgen), a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), showed the drug reduces LDL cholesterol by 43% to 64%, depending on the dose used.
Category:
Front Page
Dates:
Monday, September 16, 2013 to Sunday, September 22, 2013
Link the Feature to::
This page was last updated: May 02, 2017